日本医科大学 消化器内科学での、食道、胃、十二指腸、小腸、大腸、肝臓、胆嚢、膵臓といった消化器に関する研究活動の業績をご紹介します。

消化器内科学のご紹介

患者さまへ

医師・医療機関の方々へ

研修医の皆様へ

日本医科大学グループサイトへ

トップページ > 消化器内科学のご紹介 研究業績

研究業績

英文主要論文(2012-2017)

  • 1 Tari A, Kitadai Y, Mouri R, Takigawa H, Asaoku H, Mihara K, Takata K, Fujihara M, Yoshino T, Koga T, Fujimori S, Tanaka S, Chayama K. A watch-and-wait policy versus rituximab-combined chemotherapy in Japanese patients with intestinal follicular lymphoma. J Gastroenterol Hepatol 2018.
  • 2 Yamawaki H, Futagami S, Wakabayashi M, Sakasegawa N, Agawa S, Higuchi K, Kodaka Y, Iwakiri K. Management of functional dyspepsia: state of the art and emerging therapies. Ther Adv Chronic Dis 2018;9:23-32.
  • 3 Arai T, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, Matsuzaki Y, Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K. Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease. Hepatol Res 2018.
  • 4 Ishii N, Omata F, Nagata N, Kaise M. Effectiveness of endoscopic treatments for colonic diverticular bleeding. Gastrointest Endosc 2018;87:58-66.
  • 5 Niikura R, Yamada A, Maki K, Nakamura M, Watabe H, Fujishiro M, Oka S, Esaki M, Fujimori S, Nakajima A, Ohmiya N, Matsumoto T, Tanaka S, Koike K, Sakamoto C. Associations between drugs and small-bowel mucosal bleeding: Multicenter capsule-endoscopy study. Dig Endosc 2018;30:79-89.
  • 6 Yasui D, Murata S, Ueda T, Sugihara F, Onozawa S, Kawamoto C, Kumita S. Novel treatment strategy for advanced hepatocellular carcinoma: combination of conventional transcatheter arterial chemoembolization and modified method with portal vein occlusion for cases with arterioportal shunt: a preliminary study. Acta Radiol 2018;59:266-274.
  • 7 Atsukawa M, Tsubota A, Okubo T, Arai T, Nakagawa A, Itokawa N, Kondo C, Kato K, Hatori T, Hano H, Oikawa T, Emoto N, Abe M, Kage M, Iwakiri K. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein more reliably distinguishes liver fibrosis stages in non-alcoholic fatty liver disease than serum Mac-2 binding protein. Hepatol Res 2017.
  • 8 Atsukawa M, Tsubota A, Kato K, Abe H, Shimada N, Asano T, Ikegami T, Koeda M, Okubo T, Arai T, Nakagawa-Iwashita A, Yoshida Y, Hayama K, Itokawa N, Kondo C, Chuganji Y, Matsuzaki Y, Iwakiri K. Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema. J Gastroenterol Hepatol 2017.
  • 9 Iwakiri K. Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis. J Nippon Med Sch 2017;84:209-214.
  • 10 Kumada H, Watanabe T, Suzuki F, Ikeda K, Sato K, Toyoda H, Atsukawa M, Ido A, Takaki A, Enomoto N, Kato K, Alves K, Burroughs M, Redman R, Pugatch D, Pilot-Matias TJ, Krishnan P, Oberoi RK, Xie W, Chayama K. Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol 2017.
  • 11 Miki I, Murata S, Uchiyama F, Yasui D, Ueda T, Sugihara F, Saito H, Yamaguchi H, Murakami R, Kawamoto C, Uchida E, Kumita SI. Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy. World J Gastroenterol 2017;23:6437-6447.
  • 12 Hanada Y, Hoshino S, Hoshikawa Y, Takenouchi N, Umezawa M, Kawami N, Iwakiri K. Endoscopic diagnosis of hiatus hernia under deep inspiration is not consistent with esophageal manometric diagnosis. J Gastroenterol 2017.
  • 13 Kumada H, Watanabe T, Suzuki F, Ikeda K, Sato K, Toyoda H, Atsukawa M, Ido A, Takaki A, Enomoto N, Kato K, Alves K, Burroughs M, Redman R, Pugatch D, Pilot-Matias TJ, Krishnan P, Oberoi RK, Xie W, Chayama K. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol 2017.
  • 14 Hashimoto S, Futagami S, Yamawaki H, Kaneko K, Kodaka Y, Wakabayashi M, Sakasegawa N, Agawa S, Higuchi K, Akimoto T, Ueki N, Kawagoe T, Sato H, Nakatsuka K, Gudis K, Kawamoto C, Akamizu T, Sakamoto C, Iwakiri K. Epigastric pain syndrome accompanying pancreatic enzyme abnormalities was overlapped with early chronic pancreatitis using endosonography. J Clin Biochem Nutr 2017;61:140-145.
  • 15 Kodaka Y, Futagami S, Tatsuguchi A, Yamawaki H, Sato H, Hashimoto S, Kawagoe T, Ueki N, Nagoya H, Maruki Y, Miyake K, Gudis K, Sakamoto C, Iwakiri K. Impact of Cyclooxygenase-2 1195 G-Carrier Genotype Associated with Intestinal Metaplasia and Endoscopic Findings Based on Kyoto Classification. Digestion 2017;96:173-183.
  • 16 Toyoda H, Chayama K, Suzuki F, Sato K, Atarashi T, Watanabe T, Atsukawa M, Naganuma A, Notsumata K, Osaki Y, Nakamuta M, Takaguchi K, Saito S, Kato K, Pugatch D, Burroughs M, Redman R, Alves K, Pilot-Matias TJ, Oberoi RK, Fu B, Kumada H. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology 2017.
  • 17 Yamada A, Niikura R, Maki K, Nakamura M, Watabe H, Fujishiro M, Oka S, Fujimori S, Nakajima A, Ohmiya N, Matsumoto T, Tanaka S, Koike K, Sakamoto C. Proton pump inhibitor therapy did not increase the prevalence of small-bowel injury: A propensity-matched analysis. PLoS One 2017;12:e0182586.
  • 18 Ueki N, Futagami S, Akimoto T, Maruki Y, Yamawaki H, Kodaka Y, Nagoya H, Shindo T, Kusunoki M, Kawagoe T, Gudis K, Miyake K, Iwakiri K. Effect of Antithrombotic Therapy and Long Endoscopic Submucosal Dissection Procedure Time on Early and Delayed Postoperative Bleeding. Digestion 2017;96:21-28.
  • 19 Iwakiri K, Sakurai Y, Shiino M, Okamoto H, Kudou K, Nishimura A, Hiramatsu N, Umegaki E, Ashida K. A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis. Therap Adv Gastroenterol 2017;10:439-451.
  • 20 Shoji H, Yoshio S, Mano Y, Doi H, Sugiyama M, Osawa Y, Kimura K, Arai T, Itokawa N, Atsukawa M, Aoki Y, Fukai M, Taketomi A, Mizokami M, Kanto T. Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma. Int J Cancer 2017;141:1011-1017.
  • 21 Atsukawa M, Tsubota A, Kondo C, Shimada N, Abe H, Kato K, Okubo T, Arai T, Itokawa N, Iio E, Tanaka Y, Iwakiri K. Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C. Dig Liver Dis 2017;49:1029-1035.
  • 22 Atsukawa M, Tsubota A, Koushima Y, Ikegami T, Watanabe K, Shimada N, Sato S, Kato K, Abe H, Okubo T, Arai T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, Matsuzaki Y, Iwakiri K. Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C. Hepatol Res 2017;47:1429-1437.
  • 23 Iio E, Shimada N, Takaguchi K, Senoh T, Eguchi Y, Atsukawa M, Tsubota A, Abe H, Kato K, Kusakabe A, Miyaki T, Matsuura K, Matsunami K, Shinkai N, Fujiwara K, Nojiri S, Tanaka Y. Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy. Hepatol Res 2017;47:1308-1316.
  • 24 Nomura T, Iwakiri K, Matsutani T, Hagiwara N, Fujita I, Nakamura Y, Kanazawa Y, Makino H, Kawami N, Miyashita M, Uchida E. Characteristics and Outcomes of Laparoscopic Surgery in Patients with Gastroesophageal Reflux and Related Disease: A Single Center Experience. J Nippon Med Sch 2017;84:25-31.
  • 25 Kondo C, Atsukawa M, Tsubota A, Shimada N, Abe H, Asano T, Yoshizawa K, Okubo T, Chuganji Y, Aizawa Y, Iio E, Tanaka Y, Iwakiri K. Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease. Hepatol Res 2017;47:1165-1173.
  • 26 Hoshino S, Kawami N, Takenouchi N, Umezawa M, Hanada Y, Hoshikawa Y, Kawagoe T, Sano H, Hoshihara Y, Nomura T, Iwakiri K. Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis. Digestion 2017;95:156-161.
  • 27 Hoshino S, Takenouchi N, Hanada Y, Umezawa M, Sano H, Kawami N, Hoshikawa,Y, Kawagoe T, Nomura T, Hoshihara Y, Iwakiri K. Effects of acotiamide on esophageal motility in healthy subjects: a randomized, double-blind, placebo-controlled crossover study. Esophagus 2017;14:146-152.
  • 28 Iwakiri K, Hoshino S, Kawami N. Mechanisms underlying excessive esophageal acid exposure in patients with gastroesophageal reflux disease. Esophagus 2017;14:221-228.
  • 29 Kawami N, Takenouchi N, Umezawa M, Hoshino S, Hanada Y, Hoshikawa Y, Sano H, Hoshihara Y, Nomura T, Uchida E, Iwakiri K. Pathogenesis of Double-Dose Proton Pump Inhibitor-Resistant Non-Erosive Reflux Disease, and Mechanism of Reflux Symptoms and Gastric Acid Secretion-Suppressive Effect in the Presence or Absence of Helicobacter pylori Infection. Digestion 2017;95:140-145.
  • 30 Sugihara F, Murata S, Ueda T, Yasui D, Yamaguchi H, Miki I, Kawamoto C, Uchida E, Kumita SI. Haemodynamic changes in hepatocellular carcinoma and liver parenchyma under balloon occlusion of the hepatic artery. Eur Radiol 2017;27:2474-2481.
  • 31 Ichiyama S, Matayoshi T, Kaneko T, Shimizu A, Osada SI, Watanabe A, Kanzaki A, Mitsui K, Tsuruoka S, Iwakiri K, Kawana S, Saeki H. Successful multitarget therapy using prednisolone, mizoribine and tacrolimus for Henoch-Schonlein purpura nephritis in children. J Dermatol 2017;44:e56-e57.
  • 32 Okubo T, Atsukawa M, Tsubota A, Shimada N, Abe H, Yoshizawa K, Arai T, Nakagawa A, Itokawa N, Kondo C, Aizawa Y, Iwakiri K. Association between vitamin D deficiency and pre-existing resistance-associated hepatitis C virus NS5A variants. Hepatol Res 2017;47:641-649.
  • 33 Iio E, Shimada N, Abe H, Atsukawa M, Yoshizawa K, Takaguchi K, Eguchi Y, Nomura H, Kuramitsu T, Kang JH, Matsui T, Hirashima N, Tsubota A, Kusakabe A, Hasegawa I, Miyaki T, Shinkai N, Fujiwara K, Nojiri S, Tanaka Y. Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. J Gastroenterol 2017;52:94-103.
  • 34 Kinoshita Y, Sakurai Y, Shiino M, Kudou K, Nishimura A, Miyagi T, Iwakiri K, Umegaki E, Ashida K. Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. Curr Ther Res Clin Exp 2016;81-82:1-7.
  • 35 Kawagoe T, Maruki Y, Nagoya H, Kosugi Y, Akimoto T, Yamawaki H, Kodaka Y, Shimpuku M, Ueki N, Futagami S, Miyake K, Iwakiri K. Clinical Complete Response from Chemotherapy in an Elderly Patient with Metastatic Gastric Cancer: A Case Report. J Nippon Med Sch 2016;83:199-202.
  • 36 Kumagai E, Mano Y, Yoshio S, Shoji H, Sugiyama M, Korenaga M, Ishida T, Arai T, Itokawa N, Atsukawa M, Hyogo H, Chayama K, Ohashi T, Ito K, Yoneda M, Kawaguchi T, Torimura T, Nozaki Y, Watanabe S, Mizokami M, Kanto T. Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep 2016;6:35282.
  • 37 Fujita T, Waga E, Kitaoka K, Imagawa T, Komatsu Y, Takanashi K, Anbo F, Anbo T, Katuki S, Ichihara S, Fujimori S, Yamasaki H, Morishima Y, Sugiyama H, Katahira H. Human infection by acanthocephalan parasites belonging to the genus Corynosoma found from small bowel endoscopy. Parasitol Int 2016;65:491-3.
  • 38 Shoji H, Yoshio S, Mano Y, Kumagai E, Sugiyama M, Korenaga M, Arai T, Itokawa N, Atsukawa M, Aikata H, Hyogo H, Chayama K, Ohashi T, Ito K, Yoneda M, Nozaki Y, Kawaguchi T, Torimura T, Abe M, Hiasa Y, Fukai M, Kamiyama T, Taketomi A, Mizokami M, Kanto T. Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep 2016;6:28814.
  • 39 Iwakiri K, Kinoshita Y, Habu Y, Oshima T, Manabe N, Fujiwara Y, Nagahara A, Kawamura O, Iwakiri R, Ozawa S, Ashida K, Ohara S, Kashiwagi H, Adachi K, Higuchi K, Miwa H, Fujimoto K, Kusano M, Hoshihara Y, Kawano T, Haruma K, Hongo M, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol 2016;51:751-67.
  • 40 Futagami S, Yamawaki H, Hashimoto S, Iwakiri K. Sleep Disturbances in Functional Gastrointestinal Disorders. Intern Med 2016;55:1509-10.
  • 41 Nakagawa A, Atsukawa M, Tsubota A, Kondo C, Okubo T, Arai T, Itokawa N, Narahara Y, Iwakiri K. Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients. World J Gastroenterol 2016;22:5104-13.
  • 42 Kawamura O, Kohata Y, Kawami N, Iida H, Kawada A, Hosaka H, Shimoyama Y, Kuribayashi S, Fujiwara Y, Iwakiri K, Inamori M, Kusano M, Hongo M. Liquid-containing Refluxes and Acid Refluxes May Be Less Frequent in the Japanese Population Than in Other Populations: Normal Values of 24- hour Esophageal Impedance and pH Monitoring. J Neurogastroenterol Motil 2016;22:620-629.
  • 43 Yamawaki H, Futagami S, Kawagoe T, Maruki Y, Hashimoto S, Nagoya H, Sato H, Kodaka Y, Gudis K, Akamizu T, Sakamoto C, Iwakiri K. Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan. Neurogastroenterol Motil 2016;28:1037-47.
  • 44 Kondo C, Atsukawa M, Tsubota A, Shimada N, Abe H, Aizawa Y. Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C. J Postgrad Med 2016;62:20-5.
  • 45 Itokawa N, Atsukawa M, Tsubota A, Okubo T, Arai T, Nakagawa A, Kondo C, Iwakiri K. Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study. Int J Clin Oncol 2016;21:676-683.
  • 46 Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, Umegaki E, Iwakiri K. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 2016;43:240-51.
  • 47 Tari A, Asaoku H, Takata K, Fujimori S, Tanaka S, Fujihara M, Koga T, Yoshino T. The role of "watch and wait" in intestinal follicular lymphoma in rituximab era. Scand J Gastroenterol 2016;51:321-8.
  • 48 Atsukawa M, Tsubota A, Shimada N, Yoshizawa K, Abe H, Asano T, Ohkubo Y, Araki M, Ikegami T, Okubo T, Kondo C, Osada Y, Nakatsuka K, Chuganji Y, Matsuzaki Y, Iwakiri K, Aizawa Y. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatol Res 2016;46:450-8.
  • 49 Fujimori S, Hanada R, Hayashida M, Sakurai T, Ikushima I, Sakamoto C. Celecoxib Monotherapy Maintained Small Intestinal Mucosa Better Compared With Loxoprofen Plus Lansoprazole Treatment: A Double-blind, Randomized, Controlled Trial. J Clin Gastroenterol 2016;50:218-26.
  • 50 Mitsui K, Fujimori S, Tanaka S, Ehara A, Omori J, Akimoto N, Maki K, Suzuki M, Kosugi Y, Ensaka Y, Matsuura Y, Kobayashi T, Yonezawa M, Tatsuguchi A, Sakamoto C. Retrieval of Retained Capsule Endoscopy at Small Bowel Stricture by Double-Balloon Endoscopy Significantly Decreases Surgical Treatment. J Clin Gastroenterol 2016;50:141-6.
  • 51 Nakatsuka K, Atsukawa M, Shimizu M, Takahashi H, Kawamoto C. Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance. World J Hepatol 2015;7:2590-6.
  • 52 Atsukawa M, Tsubota A, Shimada N, Yoshizawa K, Abe H, Asano T, Ohkubo Y, Araki M, Ikegami T, Kondo C, Itokawa N, Nakagawa A, Arai T, Matsushita Y, Nakatsuka K, Furihata T, Chuganji Y, Matsuzaki Y, Aizawa Y, Iwakiri K. Influencing factors on serum 25-hydroxyvitamin D3 levels in Japanese chronic hepatitis C patients. BMC Infect Dis 2015;15:344.
  • 53 Ashida K, Sakurai Y, Nishimura A, Kudou K, Hiramatsu N, Umegaki E, Iwakiri K, Chiba T. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther 2015;42:685-95.
  • 54 Miyake K, Akimoto T, Hanada Y, Nagoya H, Kodaka Y, Ueki N, Kusunoki M, Kawagoe T, Futagami S, Takahashi Y, Takano H, Sakamoto C. Proton pump inhibitors are associated with lower gastrointestinal tract bleeding in low-dose aspirin users with ischaemic heart disease. Dig Liver Dis 2015;47:757-62.
  • 55 Fujimori S. What are the effects of proton pump inhibitors on the small intestine? World J Gastroenterol 2015;21:6817-9.
  • 56 Arai T, Atsukawa M, Tsubota A, Kondo C, Shimada N, Abe H, Itokawa N, Nakagawa A, Okubo T, Aizawa Y, Iwakiri K. Vitamin D-related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C. J Med Virol 2015;87:1904-12.
  • 57 Kawami N, Iwakiri K, Sano H, Tanaka Y, Sakamoto C. Effects of aging and acid reflux on esophageal motility. Digestion 2015;91:181-6.
  • 58 Kondo C, Atsukawa M, Tsubota A, Shimada N, Abe H, Itokawa N, Nakagawa A, Fukuda T, Matsushita Y, Nakatsuka K, Kawamoto C, Iwakiri K, Aizawa Y, Sakamoto C. Safety and efficacy of partial splenic embolization in telaprevir-based triple therapy for chronic hepatitis C. Intern Med 2015;54:119-26.
  • 59 Yamawaki H, Futagami S, Shimpuku M, Shindo T, Maruki Y, Nagoya H, Kodaka Y, Sato H, Gudis K, Kawagoe T, Sakamoto C. Leu72Met408 Polymorphism of the Ghrelin Gene Is Associated With Early Phase of Gastric Emptying in the Patients With Functional Dyspepsia in Japan. J Neurogastroenterol Motil 2015;21:93-102.
  • 60 Futagami S, Itoh T, Sakamoto C. Systematic review with meta-analysis: post-infectious functional dyspepsia. Aliment Pharmacol Ther 2015;41:177-88.
  • 61 Nomura T, Iwakiri K, Matsutani T, Hagiwara N, Fujita I, Nakamura Y, Kawami N, Miyashita M, Uchida E. Thoracoscopic long myotomy in the prone position to treat rapid esophageal contractions with normal latency. J Clin Gastroenterol 2015;49:320-2.
  • 62 Kawaguchi I, Kamae I, Soen S, Sakamoto C. Cost-Effectiveness Analysis of Celecoxib In the Treatment of Patients With Chronic Pain In Japan. Value Health 2014;17:A533.
  • 63 Matsuura M, Inamori M, Endo H, Matsuura T, Kanoshima K, Inoh Y, Fujita Y, Umezawa S, Fuyuki A, Uchiyama S, Higurashi T, Ohkubo H, Sakai E, Iida H, Nonaka T, Futagami S, Kusakabe A, Maeda S, Nakajima A. Lubiprostone decreases the small bowel transit time by capsule endoscopy: an exploratory, randomised, double-blind, placebo-controlled 3-way crossover study. Gastroenterol Res Pract 2014;2014:879595.
  • 64 Mitsui K, Yonezawa M, Tatsuguchi A, Shinji S, Gudis K, Tanaka S, Fujimori S, Sakamoto C. Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer. BMC Cancer 2014;14:863.
  • 65 Furuta K, Kohata Y, Fujiwara Y, Sugimoto M, Uotani T, Yamade M, Sahara S, Ichikawa H, Furuta T, Nio K, Iwakiri R, Inamori M, Kawamura O, Kusano M, Kato M, Kawami N, Iwakiri K, Takeuchi T, Higuchi K, Aimi M, Naora K, Fujimoto K, Arakawa T, Kinoshita Y. Intra-gastric pH following single oral administrations of rabeprazole and esomeprazole: double-blind cross-over comparison. J Clin Biochem Nutr 2014;55:178-83.
  • 66 Nakagawa A, Atsukawa M, Tsubota A, Shimada N, Abe H, Kondo C, Itokawa N, Arai T, Hashimoto S, Matsushita Y, Fukuda T, Nakatsuka K, Iwakiri K, Kawamoto C, Aizawa Y, Sakamoto C. Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy. Eur J Gastroenterol Hepatol 2014;26:1329-34.
  • 67 Yasui D, Murata S, Onozawa S, Mine T, Ueda T, Sugihara F, Kawamoto C, Uchida E, Kumita S. Improved efficacy of transcatheter arterial chemoembolization using warmed miriplatin for hepatocellular carcinoma. Biomed Res Int 2014;2014:359296.
  • 68 Shimpuku M, Futagami S, Tajima N, Yamawaki H, Maruki Y, Kodaka Y, Nagoya H, Gudis K, Kawagoe T, Sakamoto C. Impact of eating attitude and impairment of physical quality of life between tertiary clinic and primary clinic functional dyspepsia outpatients in Japan. J Neurogastroenterol Motil 2014;20:506-15.
  • 69 Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H, Kumada T, Ide T, Sata M, Aizawa Y. Predictors of response to 24-week telaprevir-based triple therapy for treatment-naive genotype 1b chronic hepatitis C patients. Gastroenterol Res Pract 2014;2014:549709.
  • 70 Sano H, Iwakiri K, Kawami N, Tanaka Y, Sakamoto C. Mechanisms of acid reflux and how refluxed Acid extends proximally in patients with non-erosive reflux disease. Digestion 2014;90:108-15.
  • 71 Nomura T, Iwakiri K, Uchida E. Thoracoscopic treatment of a patient with jackhammer esophagus. Dig Endosc 2014;26:753-4.
  • 72 Atsukawa M, Tsubota A, Shimada N, Abe H, Kondo C, Itokawa N, Nakagawa A, Iwakiri K, Kawamoto C, Aizawa Y, Sakamoto C. Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C. Dig Liver Dis 2014;46:738-43.
  • 73 Li M, Omi T, Matano Y, Fujimori S, Kawana S. The diagnostic usefulness of video capsule endoscopy in adolescent immunoglobulin A vasculitis (Henoch-Schonlein purpura). J Nippon Med Sch 2014;81:114-7.
  • 74 Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Fukuda T, Matsushita Y, Narahara Y, Osada Y, Yamaguchi H, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C. Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C. Eur J Gastroenterol Hepatol 2014;26:781-7.
  • 75 Yamawaki H, Futagami S, Shimpuku M, Sato H, Wakabayashi T, Maruki Y, Kodaka Y, Nagoya H, Shindo T, Kawagoe T, Sakamoto C. Impact of sleep disorders, quality of life and gastric emptying in distinct subtypes of functional dyspepsia in Japan. J Neurogastroenterol Motil 2014;20:104-12.
  • 76 Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Hashimoto S, Fukuda T, Matsushita Y, Narahara Y, Iwakiri K, Nakatsuka K, Kawamoto C, Sakamoto C. Serum 25-hydroxyvitamin D3 levels affect treatment outcome in pegylated interferon/ribavirin combination therapy for compensated cirrhotic patients with hepatitis C virus genotype 1b and high viral load. Hepatol Res 2014;44:1277-85.
  • 77 Fukuda T, Narahara Y, Kanazawa H, Matsushita Y, Kidokoro H, Itokawa N, Kondo C, Atsukawa M, Nakatsuka K, Sakamoto C. Effects of fasudil on the portal and systemic hemodynamics of patients with cirrhosis. J Gastroenterol Hepatol 2014;29:325-9.
  • 78 Taki Y, Kanazawa H, Narahara Y, Itokawa N, Kondo C, Fukuda T, Harimto H, Matsushita Y, Kidokoro H, Katakura T, Atsukawa M, Kimura Y, Nakatsuka K, Sakamoto C. Predictive factors for improvement of ascites after transjugular intrahepatic portosystemic shunt in patients with refractory ascites. Hepatol Res 2014;44:871-7.
  • 79 Fujimori S, Sakamoto C. Latest concepts on the association between nonsteroidal anti-inflammatory drug-induced small intestinal injury and intestinal bacterial flora. Clin J Gastroenterol 2013;6:345-51.
  • 80 Suzuki H, Kusunoki H, Kamiya T, Futagami S, Yamaguchi Y, Nishizawa T, Iwasaki E, Matsuzaki J, Takahashi S, Sakamoto C, Haruma K, Joh T, Asakura K, Hibi T. Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study): A multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial. United European Gastroenterol J 2013;1:445-52.
  • 81 Tanaka T, Ichikawa K, Maruoka T, Tomita S, Ueda H, Yamaguchi T, Shida Y, Kato H, Nagata H, Kubota K, Akimoto N, Sakamoto C, Imura J, Arita M, Tanaka H, Okamoto Y, Igarashi Y, Fujimori T. Analysis of the anatomic subsites, gender and age in unresectable advanced colorectal carcinomas in Tochigi, Japan suggests a shift in location towards the right side colon in elderly patients treated with cetuximab. Mol Clin Oncol 2013;1:291-296.
  • 82 Miyake K, Akimoto T, Kusakabe M, Sato W, Yamada A, Yamawaki H, Kodaka Y, Shinpuku M, Nagoya H, Shindo T, Ueki N, Kusunoki M, Kawagoe T, Futagami S, Tsukui T, Sakamoto C. Water-soluble vitamin deficiencies in complicated peptic ulcer patients soon after ulcer onset in Japan. J Nutr Sci Vitaminol (Tokyo) 2013;59:503-8.
  • 83 Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Narahara Y, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C. Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study. Hepat Mon 2013;13:e14872.
  • 84 Akimoto N, Fujimori T, Mitomi H, Ichikawa K, Tomita S, Tatsuguchi A, Fujimori S, Naito Z, Sakamoto C. Micropapillary pattern at the invasive front and its association with unresectable colorectal carcinomas. Dis Markers 2013;35:451-5.
  • 85 Futagami S, Yamawaki H, Shimpuku M, Izumi N, Wakabayashi T, Kodaka Y, Nagoya H, Shindo T, Kawagoe T, Sakamoto C. Impact of coexisting irritable bowel syndrome and non-erosive reflux disease on postprandial abdominal fullness and sleep disorders in functional dyspepsia. J Nippon Med Sch 2013;80:362-70.
  • 86 Harimoto H, Shimizu M, Nakagawa Y, Nakatsuka K, Wakabayashi A, Sakamoto C, Takahashi H. Inactivation of tumor-specific CD8(+) CTLs by tumor-infiltrating tolerogenic dendritic cells. Immunol Cell Biol 2013;91:545-55.
  • 87 Futagami S, Shimpuku M, Kawagoe T, Izumi N, Ohishi N, Yamawaki H, Shindo T, Nagoya H, Horie A, Kodaka Y, Gudis K, Itoh T, Sakamoto C. The preproghrelin 3056 TT genotype is associated with the feeling of hunger and low acylated ghrelin levels in Japanese patients with Helicobacter pylori-negative functional dyspepsia. Intern Med 2013;52:1155-63.
  • 88 Futagami S, Shimpuku M, Yamawaki H, Izumi N, Kodaka Y, Nagoya H, Wakabayashi T, Shindo T, Kawagoe T, Sakamoto C. Sleep disorders in functional dyspepsia and future therapy. J Nippon Med Sch 2013;80:104-9.
  • 89 Futagami S, Yamawaki H, Izumi N, Shimpuku M, Kodaka Y, Wakabayashi T, Nagoya H, Shindo T, Kawagoe T, Gudis K, Itoh T, Sakamoto C. Impact of sleep disorders in Japanese patients with functional dyspepsia (FD): nizatidine improves clinical symptoms, gastric emptying and sleep disorders in FD patients. J Gastroenterol Hepatol 2013;28:1314-20.
  • 90 Song J, Futagami S, Nagoya H, Kawagoe T, Yamawaki H, Kodaka Y, Tatsuguchi A, Gudis K, Wakabayashi T, Yonezawa M, Shimpuku M, Watarai Y, Iwakiri K, Hoshihara Y, Makino H, Miyashita M, Tsuchiya S, Li Y, S EC, Sakamoto C. Apurinic/apyrimidinic endonuclease-1 (APE-1) is overexpressed via the activation of NF-kappaB-p65 in MCP-1-positive esophageal squamous cell carcinoma tissue. J Clin Biochem Nutr 2013;52:112-9.
  • 91 Miyake K, Kusunoki M, Ueki N, Yamada A, Nagoya H, Kodaka Y, Shindo T, Kawagoe T, Gudis K, Futagami S, Tsukui T, Sakamoto C. Classification of patients who experience a higher distress level to transoral esophagogastroduodenoscopy than to transnasal esophagogastroduodenoscopy. Dig Endosc 2013;25:397-405.
  • 92 Miyake K, Kusunoki M, Ueki N, Nagoya H, Kodaka Y, Shindo T, Kawagoe T, Gudis K, Futagami S, Tsukui T, Nakamura H, Sakamoto C. Implication of antithrombotic agents on potential bleeding from endoscopically determined peptic ulcers, incidentally detected as surrogate markers for nsaids-associated ulcers complication. Dig Endosc 2013;25:25-31.

▲ページのトップに戻る

当科に関するお問い合わせは下記までお願いいたします。 日本医科大学 消化器内科学 〒113-8603東京都文京区千駄木1-1-5 TEL03-3822-2131(代表)

交通・地図はこちら